This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Lysogene Future Growth

Future criteria checks 0/6

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	34.4%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lysogene has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

LSE:0RNL - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2022	13	-7	-14	-13	N/A
3/31/2022	10	-10	-14	-14	N/A
12/31/2021	7	-14	-15	-14	N/A
9/30/2021	9	-12	N/A	N/A	N/A
6/30/2021	10	-11	-13	-13	N/A
3/31/2021	13	-8	-14	-14	N/A
12/31/2020	16	-5	-15	-14	N/A
9/30/2020	18	-4	N/A	N/A	N/A
6/30/2020	19	-2	-18	-17	N/A
3/31/2020	18	-3	-8	-7	N/A
12/31/2019	17	-4	2	2	N/A
9/30/2019	15	-5	13	14	N/A
6/30/2019	13	-6	25	25	N/A
3/31/2019	9	-8	17	17	N/A
12/31/2018	6	-11	9	9	N/A
9/30/2018	4	-14	-2	-2	N/A
6/30/2018	3	-17	-13	-13	N/A
3/31/2018	3	-17	-14	-14	N/A
12/31/2017	3	-18	-15	-15	N/A
9/30/2017	2	-15	-13	-13	N/A
6/30/2017	2	-13	-10	-10	N/A
3/31/2017	2	-10	-8	-8	N/A
12/31/2016	1	-7	-7	-7	N/A
9/30/2016	1	-6	-6	-6	N/A
6/30/2016	1	-5	-6	-6	N/A
3/31/2016	1	-5	N/A	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 0RNL's forecast earnings growth is above the savings rate (1.2%).

Earnings vs Market: Insufficient data to determine if 0RNL's earnings are forecast to grow faster than the UK market

High Growth Earnings: Insufficient data to determine if 0RNL's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 0RNL's revenue is forecast to grow faster than the UK market.

High Growth Revenue: Insufficient data to determine if 0RNL's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 0RNL's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/03/13 01:20
End of Day Share Price	2022/12/14 00:00
Earnings	2022/06/30
Annual Earnings	2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lysogene S.A. is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Eric Le Berrigaud	Bryan Garnier & Co
Lea De Cabezon	Gilbert Dupont
Delphine Le Louet	Societe Generale Cross Asset Research

This company listing is no longer active

Lysogene Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Forecast to breakeven in 2022

Recent updates

Lysogene Announces to Delist from Euronext

Lysogene Appoints Côme de La Tour du Pin as Chief Financial Officer

Lysogene Provides Updates and Topline Results from Phase 2/3 Aavance Gene Therapy Clinical Study

First half 2022 earnings released: EPS: €0.04 (vs €0.33 loss in 1H 2021)

Lysogene Announces New Board of Directors

Lysogene Provides Additional Update on Aavance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in Children with MMPS IIIA

Lysogene S.A. Provides Clinical Update on AAvance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA At the 25Th Annual ASGCT Meeting

Full year 2021 earnings released: €0.81 loss per share (vs €0.32 loss in FY 2020)

Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of Mpsiiia

Lysogene Reports Additional Positive Biomarker Data With LYS-SAF302 and Favorable Safety Data With LYS-GM101

Lysogene S.A. Provides Medical Update

Lysogene S.A. announced that it has received €4.3 million in funding from Bpifrance Investissement SAS

First half 2021 earnings released: €0.33 loss per share (vs €0.015 profit in 1H 2020)

Lysogene Announces First Patient in the United States Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis

Forecast to breakeven in 2022

Lysogene Announces First Patient Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis

Lysogene Announces Phase 3 Gene Therapy Platform Company Targeting Central Nervous System Diseases

Lysogene Reports LYS-SAF302 Biomarker Data Presented at the WORLDSymposium 2021

Lysogene S.A. Receives FDA Clearance of Investigational New Drug Application to Initiate the Gene Therapy Clinical Trial in the US with Lys-Gm101 for the Treatment of Gm1 Gangliosidosis

Lysogene S.A., Annual General Meeting, Jun 25, 2021

Lysogene Receives MHRA and Research Ethics Committee Approvals to Initiate the Gene Therapy Clinical Trial in the UK with LYS-GM101 for the Treatment of GM1 Gangliosidosis